News

Blog

Overview: Vesselon’s Transformative Co-formulation Method

Blog

Emerging Dynamics in the Biopharmaceutical Industry: Mergers & Acquisitions Trends

The Scientist

How Vesselon Can Improve the Entire Class of Radiopharmaceuticals

The Scientist

How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates

Press Release

Vesselon Virtual Town Hall: A Glimpse into the Future of Intravenous Drug Development

Press Release

Introducing the First On-site Co-Formulation Platform that Dramatically Improves How Cells Receive and Act on Drugs

Press Release

Vesselon Protects and Expands Drug Franchises

Drug maker is seeking strategic relationship to deliver unprecedented levels of efficacy by making tissues more receptive to drugs.

Drug Discovery Trends

Merck and Vesselon Preclinical Study Reports Dramatic Tumor Pharmacokinetics Findings

Complete regression of both primary and distant tumors in 44% of enrolled subjects achieved with intravenous administration.

BioSpace

Vesselon Acquires FDA Approved Lipid Microsphere Imagent

“By changing the rate of progression or stopping cancer in its tracks, Vesselon can change the cancer landscape.”

Advanced Therapeutics

Sonoporation-Enhanced Delivery of STING Agonist Induced Robust Immune Modulation & Tumor Regression

Sonoporation, the temporal cell membrane openings that can arise after ultrasound exposure, has been explored across many preclinical applications but has lacked translational momentum.